secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001104659-24-088353
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q2 2024 revenue $16.1M (+11% YoY), net loss $12.6M; reiterates FY guidance
--------------------------------------------------------------------------------

- Revenue $16.1M, +11% YoY; net loss $12.6M vs $10.8M loss in Q2 2023.
- FY 2024 revenue guidance reiterated at $74.5M-$76.5M (27%-31% YoY growth).
- Appointed Greg Firestone as CCO on May 20 to boost commercial productivity.
- Launched robotically compatible OviTex IHR for inguinal hernia market in U.S.
- Expects $3M-$7M in total NIVIS revenue share payments over next eight quarters starting Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924088353/0001104659-24-088353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924088353/tm2421368d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer